Emerging Markets 新兴市场经济与投资,逐国深度研究
← 返回South Korea
KR

Celltrion, Inc.

068270 · Korea Exchange (KRX) — KOSPI · Healthcare — Biotechnology (Biosimilars)

公司简介

Celltrion is South Korea's leading biotechnology company and a global pioneer in biosimilar drug development and manufacturing, producing biosimilars of infliximab (Remsima), trastuzumab (Herzuma), rituximab (Truxima), and other biologics. The company merged with Celltrion Healthcare in 2023 to create a fully integrated biopharmaceutical company spanning discovery to commercialization. Celltrion's biosimilar portfolio is marketed in over 100 countries.

交易所Korea Exchange (KRX) — KOSPI
股票代码068270
行业Healthcare — Biotechnology (Biosimilars)
参考市值 美元$25.00B
网站访问官网

实时报价

正在加载实时价格……

购买渠道

在其本地市场(Korea Exchange (KRX) — KOSPI),可通过以下提供该交易所准入的全球券商进行投资:

仅为准入信息参考,不构成推荐或购买要约。请向您的券商确认资格、费用及当前可用性。

South Korea的其他公司

SK hynix Inc.$1.40TSamsung Electronics Co., Ltd.$1.39TSK Square Co., Ltd.$160.00BHyundai Motor Company$87.00BSamsung Electro-Mechanics Co., Ltd.$100.00BLG Energy Solution, Ltd.$69.00BSamsung Life Insurance Co., Ltd.$54.00BSamsung C&T Corporation$49.00B

公司数据及任何实时价格均为参考性质,可能存在延迟或不准确,仅供研究参考,不构成投资建议。请以交易所、公司公告及您的券商信息为准。

主题